Biocon (Large Cap - High Growth) Share Target 2026, 2027 To 2035
|
Biocon Limited |
|||
|
Price: ₹416.05 (-0.7%) | ||
| 52 Week Low: ₹331.00 52 Week High: ₹440.40 |
|||
| Market Capital: 56,652.3 Crore (Large-cap) | |||
| Healthcare -> Biotechnology | |||
Share Price HistoryBIOCON FinancialsTomorrow TargetYearly TargetsDividend HistoryBonus HistoryNo Split
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Biocon Share Price Target For 2026
- 1.1.1: Biocon Share Price Target Table For 2026
- 1.1.2: Short-Term Technical Outlook
- 1.2: Biocon Share Price Target For 2027
- 1.2.1: Biocon Share Price Target Table For 2027
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Biocon Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
- 3: Biocon Brief Company Overview
- 4: Biocon Financial Performance
- 4.0.1: Is Biocon A Good Buy For Long Term?
Biocon, a Large Cap company in the Biotechnology Industry has delivered 71.1% returns in 3-year showing 3.7% quarterly revenue growth with 9.7% profit margin, making it a High Growth stock.
To predict the Biocon's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Biocon Share Price Target For 2026
The line chart displays the monthly closing prices of Biocon with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Biocon shares in 2026, see the table below.
Biocon Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 444.17 (+6.75%) | Volatility: ATR T1 |
| 2026 Target 2 | 438.71 (+5.44%) | Volatility: BB Upper |
| 2026 Target 1 | 416.79 (+0.17%) | Trend: EMA9 |
| Current Price | 416.05 | Biocon's share price as of 15 Jun 2026 |
| Stop Loss 1 | 406.26 (-2.36%) | Volatility: BB Lower |
| Stop Loss 2 | 398.61 (-4.2%) | 38.20% Weekly Fib Retrace |
| Stop Loss 3 | 389.40 (-6.41%) | Trend: SMA50 |
Short-Term Technical Outlook
Current Technical Position: Biocon is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 50-day moving average at ₹389.4 serves as the nearest technical reference point.
Historical Returns: 3-month: +10.34% | 6-month: +6.5% | 1-year: +17.9%
Biocon Share Price Target For 2027
The line chart displays the monthly closing prices of Biocon with a black line. The green line shows three potential target prices for 2027, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Biocon shares in 2027, see the table below.
Biocon Share Price Target Table For 2027
| Level | Value | Analysis |
|---|---|---|
| 2027 Target 3 | 444.17 (+6.75%) | Volatility: ATR T1 |
| 2027 Target 2 | 438.71 (+5.44%) | Volatility: BB Upper |
| 2027 Target 1 | 416.79 (+0.17%) | Trend: EMA9 |
| Current Price | 416.05 | Biocon's share price as of 15 Jun 2026 |
| Stop Loss 1 | 406.26 (-2.36%) | Volatility: BB Lower |
| Stop Loss 2 | 398.61 (-4.2%) | 38.20% Weekly Fib Retrace |
| Stop Loss 3 | 389.40 (-6.41%) | Trend: SMA50 |
Long-Term Technical Outlook
52-Week Range Analysis: Biocon is currently trading near its 52-week high of ₹440.4, showing strong yearly momentum.
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +17.9% | 3-year: +71.09% | 5-year: +5.03%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Biocon Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹416.05 | ||
| 2026 | ₹513.02 | +23.307294796299% | ₹520.72 |
| 2027 | ₹648.77 | +26.460956687848% | ₹658.50 |
| 2028 | ₹813.32 | +25.363379934337% | ₹825.52 |
| 2029 | ₹1,013.09 | +24.562287906359% | ₹1,028.29 |
| 2030 | ₹1,165.25 | +15.019396104986% | ₹1,182.73 |
| 2031 | ₹1,369.46 | +17.524994636344% | ₹1,390.00 |
| 2032 | ₹1,697.57 | +23.959078760971% | ₹1,723.03 |
| 2033 | ₹1,946.50 | +14.663901930406% | ₹1,975.70 |
| 2034 | ₹2,422.36 | +24.446956075006% | ₹2,458.70 |
| 2035 | ₹2,794.91 | +15.379629782526% | ₹2,836.83 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Biocon Brief Company Overview
Biocon Limited: A Biopharmaceutical Powerhouse Biocon Limited, a leading biopharmaceutical company, is a force in the industry, with a diverse product range and global reach. Key Products and Services Generics: Affordable versions of branded drugs Novel Biologics: Innovative...
treatments for complex diseases Biosimilars: Similar to branded biologics but cost-effective Research Services: Discovery, development, and manufacturing services History and Market Presence Incorporated in 1978, Biocon has its headquarters in Bengaluru, India. Today, it serves customers in over 120 countries, showcasing its global reach. Diverse Product Range Biocon's focus extends across various therapeutic areas, including diabetes, oncology, immunology, ophthalmology, and bone health diseases. Commitment to Quality Biocon is dedicated to providing high-quality, affordable healthcare solutions to meet the needs of patients worldwide.Biocon Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 40,247.3 Crore | Market valuation of Biocon's shares. |
| Revenue (TTM) | 14,894.09 Crore | Total revenue generated by Biocon over the past twelve months. |
| Net Income (TTM) | +1,439.2 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | 7.39% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | 9.66% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+3.7% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
62.76 | Company's total debt divided by total shareholder equity. |
| Total Debt | 16,770.8 Crore | Sum of Biocon's current & long-term financial obligations. |
| Total Cash | 2,650.3 Crore | Total amount of liquid funds available to Biocon. |
| Beta | 0.46 | Beta is less than 1 indicating that the Biocon's price is less volatile than the market. |
Is Biocon A Good Buy For Long Term?
Biocon, a large-cap stock with a market capitalization of ₹40,247.3 crore, shows mixed signals for long-term investment. While its ₹1,439.2 crore net profit (9.66% margin) on ₹14,894.09 crore revenue (TTM) is positive, a significant debt of ₹16,770.8 crore (Q2 2024-25) against a cash balance of ₹2,650.3 crore is concerning. Past performance is inconsistent: 50.92% return over the past 12 months contrasts sharply with a -28.78% return over the past three years. Therefore, Biocon is an average buy for the long term, requiring further due diligence considering its high debt levels.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
